Jaguar Health, Inc. (JAGX) Financial Statements (2023 and earlier)
Company Profile
| Business Address |
200 PINE STREET SUITE 400 SAN FRANCISCO, CA 94104 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 6/30/2023 MRQ | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 5,469 | 8,090 | 3,495 | 2,568 | 521 | ||||
| Cash and cash equivalents | 5,469 | 8,090 | 3,495 | 2,568 | 521 | ||||
| Restricted cash and investments | 388 | 239 | |||||||
| Receivables | 2,467 | 2,144 | 4,560 | 1,695 | 1,002 | 469 | |||
| Inventory, net of allowances, customer advances and progress billings | 7,024 | 4,900 | 2,782 | 2,129 | 3,342 | 2,073 | |||
| Inventory | 7,024 | 4,900 | 2,782 | 2,129 | 3,342 | 2,073 | |||
| Deferred costs | 13 | ||||||||
| Other undisclosed current assets | 7,361 | 21,377 | 2,360 | 1,816 | 1,238 | 497 | |||
| Total current assets: | 22,321 | 28,434 | 17,792 | 9,522 | 8,150 | 3,799 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 1,140 | 1,084 | ✕ | ✕ | |||||
| Property, plant and equipment | 557 | 650 | 677 | 710 | 761 | 1,222 | |||
| Intangible assets, net (including goodwill) | 22,439 | 22,651 | 24,337 | 26,024 | 31,711 | 38,608 | |||
| Goodwill | 5,211 | ||||||||
| Intangible assets, net (excluding goodwill) | 22,439 | 22,651 | 24,337 | 26,024 | 31,711 | 33,397 | |||
| Other undisclosed noncurrent assets | 995 | 446 | 37 | 154 | 421 | ||||
| Total noncurrent assets: | 25,131 | 24,831 | 25,051 | 26,888 | 32,892 | 39,830 | |||
| TOTAL ASSETS: | 47,452 | 53,265 | 42,843 | 36,410 | 41,042 | 43,629 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 13,973 | 12,046 | 9,252 | 8,274 | 10,354 | 9,554 | |||
| Accounts payable | 5,808 | 4,929 | 4,759 | 5,352 | 5,414 | 7,355 | |||
| Accrued liabilities | 8,165 | 7,117 | 4,493 | 2,922 | 4,939 | 2,200 | |||
| Debt | 15,883 | 3,184 | 3,789 | 7,115 | 4,846 | 1,609 | |||
| Deferred compensation liability | 112 | ||||||||
| Deferred revenue and credits | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | 5 | ||
| Other undisclosed current liabilities | 483 | 241 | 179 | 3 | 11,460 | 4,106 | |||
| Total current liabilities: | 30,339 | 15,471 | 13,220 | 15,392 | 26,659 | 15,386 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 17,744 | 25,941 | 12,421 | 450 | 10,982 | ||||
| Long-term debt, excluding current maturities | 17,744 | 25,022 | 12,421 | 450 | 10,982 | ||||
| Liabilities, other than long-term debt | 725 | ||||||||
| Operating lease, liability | 725 | 919 | ✕ | ✕ | |||||
| Other undisclosed noncurrent liabilities | (919) | ||||||||
| Total noncurrent liabilities: | 18,469 | 25,941 | 12,421 | 450 | 10,982 | ||||
| Total liabilities: | 48,808 | 41,412 | 25,641 | 15,842 | 26,659 | 26,368 | |||
| Temporary equity, carrying amount | 9,000 | ||||||||
| Equity | |||||||||
| Equity, attributable to parent, including: | (657) | 11,607 | 17,202 | 10,674 | 5,383 | 17,261 | |||
| Additional paid in capital | 266,971 | 231,100 | 184,090 | 142,046 | 99,927 | 79,655 | |||
| Accumulated other comprehensive loss | (680) | ||||||||
| Accumulated deficit | (266,948) | (219,494) | (166,899) | (133,090) | (94,551) | (62,405) | |||
| Warrants and rights outstanding | 1 | 3 | |||||||
| Other undisclosed equity, attributable to parent | 11 | 1,714 | 6 | 11 | |||||
| Equity, attributable to noncontrolling interest | (699) | 242 | |||||||
| Other undisclosed equity | 4 | 9,894 | |||||||
| Total equity: | (1,356) | 11,853 | 17,202 | 20,568 | 5,383 | 17,261 | |||
| TOTAL LIABILITIES AND EQUITY: | 47,452 | 53,265 | 42,843 | 36,410 | 41,042 | 43,629 | |||
Income Statement (P&L) ($ in thousands)
| 6/30/2023 TTM | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 11,956 | 9,385 | 5,775 | 4,416 | 4,361 | |||
| Revenue, net | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | 1,485 | |
| Cost of revenue | (2,019) | (2,333) | (3,280) | (3,816) | (2,766) | (880) | ||
| Gross profit: | 9,937 | (2,333) | 6,105 | 1,959 | 1,650 | 3,481 | ||
| Operating expenses | (44,352) | (41,076) | (27,409) | (30,259) | (35,240) | (38,608) | ||
| Other undisclosed operating income (loss) | 2,701 | (5,343) | (649) | 2,766 | 880 | |||
| Operating loss: | (34,415) | (40,708) | (26,647) | (28,948) | (30,824) | (34,247) | ||
| Nonoperating income (expense) (Other Nonoperating Income (Expense)) | 950 | (765) | 190 | 81 | 316 | 89 | ||
| Interest and debt expense | (14,910) | (9,174) | (4,656) | (10,672) | (3,173) | (1,687) | ||
| Loss from continuing operations before equity method investments, income taxes: | (48,375) | (50,647) | (31,113) | (39,539) | (33,681) | (35,845) | ||
| Other undisclosed income (loss) from continuing operations before income taxes | (20) | (1,953) | (2,696) | 1,009 | 1,535 | 695 | ||
| Loss from continuing operations before income taxes: | (48,395) | (52,600) | (33,809) | (38,529) | (32,146) | (35,150) | ||
| Income tax expense (benefit) | (10) | 13,181 | ||||||
| Loss from continuing operations: | (48,395) | (52,600) | (33,809) | (38,539) | (32,146) | (21,969) | ||
| Loss before gain (loss) on sale of properties: | ✕ | (52,600) | (33,809) | (38,539) | (32,146) | (21,969) | ||
| Net loss: | (48,395) | (52,600) | (33,809) | (38,539) | (32,146) | (21,969) | ||
| Net income attributable to noncontrolling interest | 941 | 5 | ||||||
| Net loss attributable to parent: | (47,454) | (52,595) | (33,809) | (38,539) | (32,146) | (21,969) | ||
| Preferred stock dividends and other adjustments | (995) | |||||||
| Other undisclosed net income available to common stockholders, basic | 995 | |||||||
| Net loss available to common stockholders, diluted: | (47,454) | (52,595) | (33,809) | (38,539) | (32,146) | (21,969) | ||
Comprehensive Income ($ in thousands)
| 6/30/2023 TTM | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (48,395) | (52,600) | (33,809) | (38,539) | (32,146) | (21,969) | ||
| Other comprehensive loss | ||||||||
| Other undisclosed comprehensive loss | (680) | |||||||
| Comprehensive loss: | (49,075) | (52,600) | (33,809) | (38,539) | (32,146) | (21,969) | ||
| Comprehensive income, net of tax, attributable to noncontrolling interest | 941 | 5 | ||||||
| Comprehensive loss, net of tax, attributable to parent: | (48,134) | (52,595) | (33,809) | (38,539) | (32,146) | (21,969) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.